Keeping Track: More Rx-To-OTC Switches On Deck After US FDA’s OTC Narcan Approval; Iovance Looks To Bring Cell Therapy To Melanoma

Rx-to-OTC switches have been taking a rare turn at center stage in the news cycle, with the US FDA’s first nonprescription naloxone approval in a starring role.

The 29 March FDA approval of Emergent BioSolutions, Inc.’s Narcan 4mg naloxone nasal spray is a culmination of a...